Full title: A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harbouring ALK, ROS1, NTRK1-3 Alterations
Age: Phase 1: under 12 ; Phase 2: 12-25 years
Phase: 1/2
Locations:
- Cardiff – University Hospital of Wales
- Glasgow – Royal Hosp. for Children
- London – The Royal Marsden NHS Foundation Trust ; Great Ormond Street Hospital
- Liverpool – Alder Hey Children’s NHS Foundation Trust
This study will look at the effects of a drug called repotrectinib to see how safe it is and how well it works in children and young adults with advanced cancers, including sarcomas that have specific genetic changes. It will includes patients whose tumours have ALK, ROS1 or NTRK gene alternations and will assess the best dose of the drug and its effectiveness.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
